Clinical Trial

The Combined Effect of the Mediterranean Diet and Intermittent Fasting on Hypertension

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 24, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Hypertension (HT) is an important risk factor for cardiovascular diseases (CVD) and death. Approximately 16.9 million people in Turkey have HT. Nutritional habits play an important role in the development of HT. DASH (Dietary Approaches to Stop Hypertension) and the Mediterranean diet (MD) have been found to be effective in lowering blood pressure and reducing cardiometabolic risks. The DASH diet stands out with its low sodium, saturated fat, simple sugar and cholesterol content, while it is rich in fiber, potassium, magnesium and anti-inflammatory components. The MD is based on healthy foods such as olive oil, vegetables, fruits, fish and nuts, and contains antioxidants and healthy fatty acids. This study will investigate whether the sodium-restricted MD can offer a model comparable to DASH. In addition, the effects of the intermittent fasting diet (IFD) model alone and in combination with the MD on blood pressure will be examined. It has been observed that IFD reduces blood pressure by reducing energy intake and acting on the autonomic nervous system. The aim of this project is to evaluate the effects of MD, IFD and both of them on hypertension and to present a new and original approach in this field.
Trial Details
NCT Number NCT07189637
Lead Sponsor Nadide Gizem Tarakci Filiz
Collaborators: Medipol University, Istanbul Medipol University Hospital, Fenerbahce University
Conditions Hypertension
Enrollment 48 participants
Start Date 2025-11-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-24